comparemela.com
Latest Breaking News On - Michiel van der heijden research group - Page 1 : comparemela.com
Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer
Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.
United-states
Netherlands
America
Padcev-keytruda
Michiels-van
Michiel-van-der-heijden-research-group
Netherlands-cancer-institute
Drug-administration
Cancers-symposium
Der-heijden
Michiel-van
Heijden-research-group
vimarsana © 2020. All Rights Reserved.